Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2022-03-21 Investor Presentation
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Botanix to present at Switzer Virtual Investor Day 2 pages 139.3KB
Investor Presentation Classification · 85% confidence The document is a press release announcing Botanix Pharmaceuticals' participation in the Switzer Small and Micro Cap Virtual Investor Day, including details about the presentation and a reference to a previously released corporate presentation dated 14 March 2022. It does not contain any financial statements, detailed financial data, or regulatory filings. The document is short (3833 characters) and primarily serves as an announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. Therefore, it fits best as an Investor Presentation (IP) announcement or related communication. However, since the actual presentation is not included and this is an announcement of participation and presentation timing, it aligns most closely with the Investor Presentation (IP) category, which includes detailed presentations for investors focusing on financials, strategy, and market position, or announcements thereof. Given the content, the best fit is Investor Presentation (IP).
2022-03-21 English
Investor Presentation 22 pages 3.1MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' dated 14 March 2022 and contains detailed information about the company's clinical pipeline, market opportunities, financial position, management team, and strategic outlook. It includes slides and data typically found in presentations aimed at investors, such as market size, product pipeline stages, and corporate overview. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The document is not a brief announcement or a certification but a comprehensive presentation for investors. Therefore, the document fits the category of an Investor Presentation (IP).
2022-03-13 English
Botanix to present at ShareCafe - Hidden Gems Webinar 11 pages 1.1MB
Investor Presentation Classification · 100% confidence The document is an investor presentation dated February 2022 by Botanix Pharmaceuticals. It includes detailed information about the company's clinical pipeline, market opportunities, product development stages, and upcoming milestones. The text explicitly mentions that it is an "Investor Presentation" and contains slides with data on pharmaceutical focus, clinical development stages, market sizes, and clinical study designs. There is no indication that this is a regulatory filing, earnings release, or any other type of report. The document is not a brief announcement or a certification but a detailed presentation aimed at investors. Therefore, the appropriate classification is Investor Presentation (IP).
2022-02-24 English
Notification of cessation of securities - BOT 4 pages 24.1KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation of securities, specifically options that have expired without exercise or conversion. It provides details about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement related to changes in the company's securities, not a financial report or detailed analysis. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about securities status changes and does not fall under more specific categories like capital changes (SHA) or director dealings (DIRS). The document length is short and it is a straightforward notification rather than a report or detailed filing.
2022-02-21 English
Change of Director's Interest Notice SW 3 pages 226.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of securities held before and after the change, nature of the change, and dates. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is under 5,000 characters and contains detailed transaction information, not just an announcement or certification. Therefore, it is classified as a Director's Dealing report.
2022-02-21 English
Half Yearly Report and Accounts 22 pages 786.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half-yearly report Botanix Pharmaceuticals Limited' and references the half-year ended 31 December 2021. It contains detailed financial data including profit/loss, net tangible assets, dividends, and a comprehensive Directors' Report. It also includes consolidated financial statements and an independent auditor's report. The content is consistent with a comprehensive interim financial report covering a period shorter than a full fiscal year, with substantive financial data and analysis. The document is approximately 15,000 characters long, indicating it is the full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2022-02-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.